BioSpace News Archive

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, announced the appointment of Peter K Honig, MD, MPH, to the Board of Directors, effective December 3, 2021.

MEI Pharma, Inc. announced that it has closed the previously announced underwritten public offering of 20,125,000 shares of its common stock, which includes 2,625,000 shares of common stock sold as a result of the full exercise by the underwriters of an option to purchase additional shares of common stock, at $2.60 per share for total gross proceeds, before underwriting commissions and estimated expenses, of approximately $52,325,000.

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced positive top-line results from the pivotal, Phase 3 Lavender™ study evaluating the efficacy and safety of trofinetide in 187 girls and young women aged 5-20 years with Rett syndrome.

ImmunoGen, Inc. announced the closing of its previously announced underwritten public offering of 17,486,364 shares of its common stock, which reflects the exercise in full by the underwriters of their option to purchase up to 5,850,000 additional shares of common stock, and pre-funded warrants to purchase 27,363,636 shares of its common stock.

Shineco, Inc. announced that it has entered into a securities purchase agreement for the sale of Gross Proceeds US$2.0 million of its registered common stock at a price of $6.8546 per share with GHS Investments, LLC, a leading private investment and management group providing financial solutions for high potential small cap enterprises.

Precision Optics Corporation, Inc., a leading designer and manufacturer of advanced optical instruments for the medical and defense industries, announced it will be participating in the Lytham Partners Winter 2021 Investor Conference taking place from December 13-16, 2021.

Scientific Industries, Inc., a life sciences tool provider, and a developer of digitally simplified bioprocessing products, announced that it will be participating in the Lytham Partners Winter 2021 Investor Conference taking place from December 13-16, 2021.

Context Therapeutics Inc. announced that it has closed its previously announced private placement for the sale of 5,000,000 shares of common stock of Context Therapeutics together with warrants to purchase 5,000,000 shares of common stock, which resulted in gross proceeds to Context Therapeutics of approximately $31.25 million, before deducting offering expenses.

Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune and other major diseases, announces that results of a phase 1 clinical trial of IBI362 (LY3305677).

Today, Akeso, Inc. (9926.HK) announced that the company will support an investigator-initiated study (IIS) to evaluate the efficacy and safety of Akeso’s novel, first-in-class anti-PD-1/CTLA-4 bispecific antibody, cadonilimab, for the treatment of neuroendocrine cervical carcinoma in the United States.